FENNEC PHARMACEUTICALS INC.·4

Feb 2, 4:54 PM ET

Raykov Rosty 4

4 · FENNEC PHARMACEUTICALS INC. · Filed Feb 2, 2026

Research Summary

AI-generated summary of this filing

Updated

Fennec (FENC) Director Rosty Exercises Options, Sells Shares

What Happened

  • Director Rosty exercised 15,598 stock options at an exercise price of $2.45 per share, costing $38,215, and a related disposition tied to that exercise is reported. Separately, he sold 10,349 shares in an open‑market sale at $7.76 per share, receiving $80,308. The filing notes the exercise and related transactions were made under a 10b5‑1 trading plan and that some shares were sold to satisfy tax withholding obligations.

Key Details

  • Transaction date: 2026-02-02
  • Option exercise (acquired): 15,598 shares @ $2.45 = $38,215 (footnote: exercised under a 10b5‑1 plan adopted 9/19/2025)
  • Open‑market sale (disposed): 10,349 shares @ $7.76 = $80,308
  • Footnote indicates shares were sold to satisfy tax obligations on the option exercise
  • Shares owned after the transactions: not specified in the supplied summary of the filing
  • Filing date matches the transaction date (no late filing indicated in the provided data)

Context

  • This was an option exercise (an acquisition) combined with share sales. Selling shares to cover taxes or immediately after exercising options is a common administrative action (often called a cashless exercise/tax withholding) and does not necessarily indicate a change in the insider’s view of the company. The presence of a 10b5‑1 plan means the exercise and sales were executed under a prearranged trading plan adopted on September 19, 2025.

Insider Transaction Report

Form 4
Period: 2026-02-02
Raykov Rosty
Director
Transactions
  • Exercise/Conversion

    Common shares

    [F1]
    2026-02-02$2.45/sh+15,598$38,215108,826 total
  • Sale

    Common shares

    [F2]
    2026-02-02$7.76/sh10,349$80,30898,477 total
  • Exercise/Conversion

    Stock Options

    [F3]
    2026-02-02$2.45/sh15,598$38,2151,602,988 total
    Exercise: $2.45From: 2016-07-05Exp: 2026-07-05options (15,598 underlying)
Footnotes (3)
  • [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025.
  • [F2]Shares sold to satisfy tax obligation on option exercise.
  • [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025.
Signature
/s/ Rosty Raykov|2026-02-02

Documents

1 file
  • 4
    form4-02022026_090248.xmlPrimary